Circle Pharma to Present Late-Breaking Data at AACR 2025 Demonstrating Mechanism of Action for Novel Cyclin A/B RxL Inhibitors

On April 22, 2025 Circle Pharma, a clinical-stage biopharmaceutical company focused on developing cell-permeable macrocycle therapeutics, reported a late-breaking poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025 in Chicago, Illinois (Press release, Circle Pharma, APR 22, 2025, View Source;utm_medium=rss&utm_campaign=circle-pharma-to-present-late-breaking-data-at-aacr-2025-demonstrating-mechanism-of-action-for-novel-cyclin-a-b-rxl-inhibitors [SID1234652013]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster will present new mechanistic insights into the anti-cancer activity of cyclin A/B RxL inhibitors, including their impact on DNA repair pathways and mitotic progression in E2F-high cancers. Circle Pharma’s CID-078, an oral macrocycle Cyclin A/B RxL inhibitor, is being evaluated in a Phase 1 clinical study (NCT06577987).

Presentation Details
Title: Anti-cancer effect of Cyclin A/B RxL inhibitors is mediated in part by disruption
of the ATR/Chk1 DNA repair pathway

Session: Late-Breaking Research: Experimental and Molecular Therapeutics 3

Session Start: 4/29/2025 9:00:00 AM CT

Session End: 4/29/2025 12:00:00 PM CT
Location: Poster Section 52
Poster Board Number: 19
Abstract Number: LB296

The study, led by researchers from Circle Pharma in collaboration with the University of Oxford and Dana-Farber Cancer Institute, highlights the dual mechanism by which Cyclin A/B RxL inhibitors induce tumor regression.

Contributing Authors:
Catherine E. Gleason, Ranya Odeh, Frances Hamkins-Indik, Iolanda Vendrell, Roman Fischer, Benedikt Kessler, Shilpa Singh, Matthew Oser, Marie Evangelista, and Pablo D. Garcia, Circle Pharma Inc., South San Francisco, CA, University of Oxford, UK,
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA